379 related articles for article (PubMed ID: 30724782)
1. Dual Modality Radiation With External Beam Radiation Therapy and Transarterial Radioembolization for Hepatocellular Carcinoma With Gross Vascular Invasion.
McGee HM; King MJ; Özbek U; Olson A; Kim E; Fischman AM; Schwartz M; Rosenzweig KE; Buckstein M
Am J Clin Oncol; 2019 Apr; 42(4):367-374. PubMed ID: 30724782
[TBL] [Abstract][Full Text] [Related]
2. Patterns of Care and Outcomes of Definitive External Beam Radiotherapy and Radioembolization for Localized Hepatocellular Carcinoma: A Propensity Score-adjusted Analysis.
Bitterman DS; Sanford NN; Niemierko A; Mahal BA; Qadan M; Ganguli S; Blaszkowsky LS; Zhu AX; Hong TS; Devlin PM; Goyal L; Wo JY
Am J Clin Oncol; 2019 Jul; 42(7):564-572. PubMed ID: 31166209
[TBL] [Abstract][Full Text] [Related]
3. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
Spreafico C; Sposito C; Vaiani M; Cascella T; Bhoori S; Morosi C; Lanocita R; Romito R; Chiesa C; Maccauro M; Marchianò A; Mazzaferro V
J Hepatol; 2018 Apr; 68(4):724-732. PubMed ID: 29331342
[TBL] [Abstract][Full Text] [Related]
4. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
[TBL] [Abstract][Full Text] [Related]
5. The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective study.
Abdallah MA; Wongjarupong N; Hassan MA; Taha W; Abdalla A; Bampoh S; Onyirioha K; Nelson M; Glubranson LA; Wiseman GA; Fleming CJ; Andrews JC; Mahipal A; Roberts LR
Expert Rev Gastroenterol Hepatol; 2020 Jul; 14(7):619-629. PubMed ID: 32490691
[TBL] [Abstract][Full Text] [Related]
6. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.
Kim DY; Han KH
Hepatol Int; 2016 Nov; 10(6):883-892. PubMed ID: 27126821
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Liver Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma After Segmental Transarterial Radioembolization.
Hardy-Abeloos C; Lazarev S; Ru M; Kim E; Fischman A; Moshier E; Rosenzweig K; Buckstein M
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):968-976. PubMed ID: 31536781
[TBL] [Abstract][Full Text] [Related]
9. Resin Versus Glass Microspheres for
Van Der Gucht A; Jreige M; Denys A; Blanc-Durand P; Boubaker A; Pomoni A; Mitsakis P; Silva-Monteiro M; Gnesin S; Lalonde MN; Duran R; Prior JO; Schaefer N
J Nucl Med; 2017 Aug; 58(8):1334-1340. PubMed ID: 28082436
[TBL] [Abstract][Full Text] [Related]
10. Transarterial chemoembolization combined with apatinib versus transarterial chemoembolization alone for hepatocellular carcinoma with macroscopic vascular invasion: A propensity score matching analysis.
Shen L; Chen S; Qiu Z; Qi H; Yuan H; Cao F; Xie L; Chen Q; Li W; Fan W
J Cancer Res Ther; 2020 Sep; 16(5):1063-1068. PubMed ID: 33004748
[TBL] [Abstract][Full Text] [Related]
11. Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Song JE; Jung KS; Kim DY; Song K; Won JY; Lee HW; Kim BK; Kim SU; Park JY; Ahn SH; Seong J; Han KH
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):396-406. PubMed ID: 28871990
[TBL] [Abstract][Full Text] [Related]
12. Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma.
Johnson GE; Monsky WL; Valji K; Hippe DS; Padia SA
J Vasc Interv Radiol; 2016 Aug; 27(8):1123-9. PubMed ID: 27321889
[TBL] [Abstract][Full Text] [Related]
13. Influence of tumor thrombus location on the outcome of external-beam radiation therapy in advanced hepatocellular carcinoma with macrovascular invasion.
Hou JZ; Zeng ZC; Zhang JY; Fan J; Zhou J; Zeng MS
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):362-8. PubMed ID: 22381903
[TBL] [Abstract][Full Text] [Related]
14. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
[TBL] [Abstract][Full Text] [Related]
15. Quantification of Blood Pressure Changes in the Vascular Compartment When Using an Anti-Reflux Catheter during Chemoembolization versus Radioembolization: A Retrospective Case Series.
Rose SC; Narsinh KH; Newton IG
J Vasc Interv Radiol; 2017 Jan; 28(1):103-110. PubMed ID: 27840042
[TBL] [Abstract][Full Text] [Related]
16. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience.
Salem R; Gabr A; Riaz A; Mora R; Ali R; Abecassis M; Hickey R; Kulik L; Ganger D; Flamm S; Atassi R; Atassi B; Sato K; Benson AB; Mulcahy MF; Abouchaleh N; Asadi AA; Desai K; Thornburg B; Vouche M; Habib A; Caicedo J; Miller FH; Yaghmai V; Kallini JR; Mouli S; Lewandowski RJ
Hepatology; 2018 Oct; 68(4):1429-1440. PubMed ID: 29194711
[TBL] [Abstract][Full Text] [Related]
17. Locoregional Therapy of Hepatocellular-Cholangiocarcinoma versus Hepatocellular Carcinoma: A Propensity Score-Matched Study.
Huang YH; Park BV; Chen YF; Gaba RC; Guzman G; Lokken RP
J Vasc Interv Radiol; 2019 Sep; 30(9):1317-1324. PubMed ID: 31375450
[TBL] [Abstract][Full Text] [Related]
18. Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis.
Hur MH; Cho Y; Kim DY; Lee JS; Kim GM; Kim HC; Sinn DH; Hyun D; Lee HA; Seo YS; Lee IJ; Park JW; Kim YJ
Clin Mol Hepatol; 2023 Jul; 29(3):763-778. PubMed ID: 37254488
[TBL] [Abstract][Full Text] [Related]
19. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?
El Fouly A; Ertle J; El Dorry A; Shaker MK; Dechêne A; Abdella H; Mueller S; Barakat E; Lauenstein T; Bockisch A; Gerken G; Schlaak JF
Liver Int; 2015 Feb; 35(2):627-35. PubMed ID: 25040497
[TBL] [Abstract][Full Text] [Related]
20. Transarterial chemoembolization versus surgery/radiofrequency ablation for recurrent hepatocellular carcinoma with or without microvascular invasion.
Jin YJ; Lee JW; Lee OH; Chung HJ; Kim YS; Lee JI; Cho SG; Jeon YS; Lee KY; Ahn SI; Shin WY
J Gastroenterol Hepatol; 2014 May; 29(5):1056-64. PubMed ID: 24372785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]